Taken together, the results of these studies demonstrate that PPARγ agonists can be used to inhibit IL-6-dependent crosstalk between myeloma cells and BMSCs [207, 211, 212], validating novel therapeutic strategies that target the tumor-stromal microenvironment. Here, PPARG is linked to plasma cell myeloma.